SlideShare a Scribd company logo
PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST
, 2017
page 1 of 7
‘Corporate Reputation of Pharma in 2016—
The Patient Perspective'
EMBARGOED PRESS RELEASE 6AM, GMT, TUESDAY MARCH 21ST, 2017
~ CONTACT: ALEX WYKE ~ TEL: +44 (0)1547-520-965 ~ EMAIL: REPORT@PATIENT-VIEW.COM
ABOUT THIS REPORT AND SURVEY
 Results drawn from survey conducted: November 2016 to early-February 2017.
 Feedback from the patient groups surveyed: 1,463 patient groups; 46+ specialties; 105 countries.
 Survey conducted in 16 languages: Japanese, Korean and Hungarian were new additions in
2016 (and had an impact on the survey results).
 Industry analyses: compared with other healthcare sectors; assessed for a wide range of
activities, and across different geographic areas.
 Recommendations from respondent patient groups: how to improve corporate reputation.
 Company analyses: 47 pharma companies, assessed on seven indicators of corporate reputation.
 Pharma companies tell their own story on patient centricity: AbbVie; Eisai; Janssen
(Pharmaceutical Companies of Johnson & Johnson); LEO Pharma; Lundbeck; Novartis; Servier; and
ViiV Healthcare.
 Report length: 227 pages.
For the purposes of this report, the phrase 'corporate reputation' is defined as the extent to which
pharma companies are meeting the expectations of patients and patient groups.
PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST
, 2017
page 2 of 7
The 47 companies analysed in this 2016 report
AbbVie I Allergan I Almirall I Amgen I Astellas Pharma I AstraZeneca I Bayer I Bial (new for 2016) I Biogen I
Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Chiesi Farmaceutici I Eisai I Eli Lilly (Lilly) I Ferring I
Gedeon Richter I Gilead Sciences I Grifols I Grünenthal I GSK I Hospira I Ipsen I Janssen (Pharmaceutical
Companies of Johnson & Johnson) I LEO Pharma I Lundbeck I Mallinckrodt I Menarini I Merck & Co I
Merck KGaA I Mylan I Novartis I Novo Nordisk I Octapharma I Otsuka I Pfizer I Roche I Sandoz I Sanofi I
Servier I Shire I Stada Arzneimittel I Takeda I Teva I UCB I Valeant I ViiV Healthcare.
ASSESSING THE PHARMA INDUSTRY AND ITS
COMPANIES
The pharma industry's performance at
corporate reputation is assessed by three types
of measures (2011-2016)
1. How pharma's corporate reputation
compares with that of seven other
healthcare-industry sectors.
2. How pharma's corporate reputation has
changed over the past five years.
3. How good or bad the pharma industry is at
various activities.
The seven indicators of corporate reputation
used to assess the 47 pharma companies are:
1. Patient centricity.
2. .Patient information.
3. Patient safety.
4. Useful products.
5. Transparency.
6. Integrity.
7. Effectiveness of patient-group relationships
(NEW for the 2016 analysis).
HOW DID INDUSTRY FARE?
Patient groups judged that the pharma industry's corporate reputation fell in 2016 - after having
reached a high in 2015 (as assessed over a 2011-2016 six-year period).
 Just 37.9% of respondent patient groups thought that the pharma industry had an
"Excellent" or "Good" corporate reputation in 2016. 44.7% of patient groups had said the same
in 2015.
 In 2016, only 23% of patient groups thought that pharma's corporate reputation had improved
over the previous five years. 28% of patient groups had said the same in 2015.
 In 2016 (as in 2015), pharma continued to be ranked 5th out of eight healthcare sectors (ahead
only of generics, for-profit, and not-for-profit health insurers).
 Patient groups thought that pharma's ability to conduct activities of importance to patient
groups declined in 2016. Patient groups were more sceptical in 2016 even about pharma's ability
to innovate (an important patient-group measure of confidence in the industry).
 Regarding the quality of pharma's innovation across several geographic areas: patient groups
in New Zealand would seem to have the least confidence in pharma's ability to innovate; those
in Greece, the most.
PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST
, 2017
page 3 of 7
Patient groups’ perceptions of the pharma industry 2011-2016, at various activities,
Percentage of total responses each year, that stated the pharma industry was 'Excellent' or 'Good' at each
activity
PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST
, 2017
page 4 of 7
HOW CAN PHARMA IMPROVE?
Patient-groups' perceptions of the
pharma industry (2011-2016) at
innovation
For different countries/regions;
Percentage of total responses each
year, that stated the pharma industry
was 'Excellent' or 'Good' at each
activity
[number in brackets is the number
of respondent patient groups]
14-point plan proposed
by the 460+ patient
groups that commented
on how pharma can
improve its patient
centricity Numbers next
to green bars refer to the
frequency of comments
PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST
, 2017
page 5 of 7
HOW COMPANIES PERFORMED
Corporate brand awareness
The number/percentage of patient groups claiming familiarity with individual pharma companies gives an
idea of a company's brand awareness within the patient community. In 2016:
 63% of the 1,463 respondent patient groups claimed familiarity with Pfizer - making the company
the most well-known worldwide among patient groups.
 Following up were Novartis (60%), Roche (54%), Bayer (51%), and Merck & Co (42%). These five
companies rank both high and low for corporate reputation in 2016. Thus, the results show that
little correlation exists (at least among the larger multinationals) between familiarity and
corporate reputation, as perceived by patient groups.
Respondent patient groups were also asked to state which companies they had worked with in the past
five years. In 2016:
 Novartis ranked top, with 395 patient groups stating that they had worked with the company
within the past five years.
 Following up were Pfizer (329), Roche (316), AbbVie (247), Janssen (242), and Bayer (206).
Companies with the best corporate reputation among patient groups in 2016
 Overall top-tier companies: The average performance of each company across the seven
indicators of corporate reputation allowed them to be positioned into one of three tiers. Eleven
companies made it into the top tier, with averages of 20%+. (SEE TABLE ON NEXT PAGE)
 ViiV Healthcare has made the remarkable achievement of being ranked not only 1st overall in
2016, but also 1st for all seven indicators of corporate reputation.
 AbbVie ranks overall 2nd in 2016, and is also 2nd for six of the seven indicators of corporate
reputation (the exception was high-quality products, for which it ranked 3rd).
 New to the overall top tier is Grifols, up from 25th in 2015 to overall 6th in 2016. Shire is up from
21st in 2015 to overall 10th in 2016. The radical jump for both companies was due to positive
feedback for them from haemophilia patient groups, which responded in greater numbers in
2016.
 Pfizer has slipped out of the top tier, dropping one place to overall 12th in 2016. Pfizer, though,
ranks in the top tier for four of the seven indicators of corporate reputation.
Other high flyers
 The responses in 2016 from haemophilia patient groups also increased the rankings of
Octapharma (up from 42nd in 2015 to overall 24th in 2016).
PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST
, 2017
page 6 of 7
 Allergan's jump in the rankings, from 39th in 2015 to overall 26th in 2016, was primarily due to
favourable feedback from patient groups in Scandinavia, and from those based in South
Asia/South-East Asia, as well as from the 35 respondent neurological patient groups worldwide
that were familiar with the company.
 Amgen, which jumped from 26th in 2015 to overall 19th in 2016, gained positive feedback from
the 107 respondent cancer patient groups familiar with the company.
 Chiesi jumped from 36th in 2015 to overall 30th in 2016, primarily due to positive feedback from
rare-disease patient groups.
 GSK jumped from 17th in 2015 to overall 13th in 2016, due to positive feedback from 36 patient
groups from South Asia/South-East Asia, and 39 respiratory/allergy patient groups worldwide.
Companies with the best corporate reputation among patient groups in 2016
High flyers
Company
Rank
2016
Rank
2015
Difference
Gedeon Richter 20th 43th 23
Grifols 6th 25th 19
Octapharma 24th 42nd 18
Allergan 26th 39th 13
Shire 10th 21st 11
Amgen 19th 26th 7
Chiesi 30th 36th 6
GSK 13th 17th 4
PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST
, 2017
page 7 of 7
PROFILE OF RESPONDENT PATIENT GROUPS
Numbers of patient groups

More Related Content

What's hot

Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019
PhRMA
 
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
Global Study Solutions - 9901366442
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020
PhRMA
 
Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020
PhRMA
 
Differential pricing of_pharmaceuticals_1561916577
Differential pricing of_pharmaceuticals_1561916577Differential pricing of_pharmaceuticals_1561916577
Differential pricing of_pharmaceuticals_1561916577
RamiroCazco2
 
National trends..
National trends..National trends..
National trends..
Georgi Daskalov
 
The Amazonisation of Healthcare - Start with the Customer & Work Backwards
The Amazonisation of Healthcare - Start with the Customer & Work BackwardsThe Amazonisation of Healthcare - Start with the Customer & Work Backwards
The Amazonisation of Healthcare - Start with the Customer & Work Backwards
Anup Soans
 
Global Pharmaceutical Strategy
Global Pharmaceutical StrategyGlobal Pharmaceutical Strategy
Global Pharmaceutical Strategy
Dr Amit Rangnekar
 
5 Myths of Drug Delivery[1]
5 Myths of Drug Delivery[1]5 Myths of Drug Delivery[1]
5 Myths of Drug Delivery[1]
Elan Drug Technologies
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019
PhRMA
 
"The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo: How d...
"The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo:  How d..."The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo:  How d...
"The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo: How d...
The Partnership For Safe Medicines
 
PAN_Celgene in China
PAN_Celgene in ChinaPAN_Celgene in China
PAN_Celgene in China
Tamra Sami
 
Generic medicines in india promulgating growth & access
Generic medicines in india promulgating growth & accessGeneric medicines in india promulgating growth & access
Generic medicines in india promulgating growth & access
Shushmul Maheshwari
 

What's hot (13)

Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019
 
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020
 
Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020
 
Differential pricing of_pharmaceuticals_1561916577
Differential pricing of_pharmaceuticals_1561916577Differential pricing of_pharmaceuticals_1561916577
Differential pricing of_pharmaceuticals_1561916577
 
National trends..
National trends..National trends..
National trends..
 
The Amazonisation of Healthcare - Start with the Customer & Work Backwards
The Amazonisation of Healthcare - Start with the Customer & Work BackwardsThe Amazonisation of Healthcare - Start with the Customer & Work Backwards
The Amazonisation of Healthcare - Start with the Customer & Work Backwards
 
Global Pharmaceutical Strategy
Global Pharmaceutical StrategyGlobal Pharmaceutical Strategy
Global Pharmaceutical Strategy
 
5 Myths of Drug Delivery[1]
5 Myths of Drug Delivery[1]5 Myths of Drug Delivery[1]
5 Myths of Drug Delivery[1]
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019
 
"The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo: How d...
"The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo:  How d..."The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo:  How d...
"The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo: How d...
 
PAN_Celgene in China
PAN_Celgene in ChinaPAN_Celgene in China
PAN_Celgene in China
 
Generic medicines in india promulgating growth & access
Generic medicines in india promulgating growth & accessGeneric medicines in india promulgating growth & access
Generic medicines in india promulgating growth & access
 

Similar to Corporate reputation of pharma in 2016

Biosimilars discussion on Twitter
Biosimilars discussion on TwitterBiosimilars discussion on Twitter
Biosimilars discussion on Twitter
Silja Chouquet
 
Marketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA ProgramMarketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA Program
jreidglass1
 
Ethics in the Workplace Case Competition
Ethics in the Workplace Case CompetitionEthics in the Workplace Case Competition
Ethics in the Workplace Case Competition
Supriya Nair
 
Insights success the 10 fastest growing pharmaceutical companies oct 2017
Insights success the 10 fastest growing pharmaceutical companies oct 2017Insights success the 10 fastest growing pharmaceutical companies oct 2017
Insights success the 10 fastest growing pharmaceutical companies oct 2017
Insights success media and technology pvt ltd
 
Kim_Dongok_VRX_ENDP
Kim_Dongok_VRX_ENDPKim_Dongok_VRX_ENDP
Kim_Dongok_VRX_ENDP
Dongok Kim
 
Final Campaign for IMC 618 at WVU
Final Campaign for IMC 618 at WVUFinal Campaign for IMC 618 at WVU
Final Campaign for IMC 618 at WVU
Aaron Weese
 
EVA pharma document
EVA pharma documentEVA pharma document
EVA pharma document
AkramMad1
 
Pharmaceutical drugs global market report 2018
Pharmaceutical drugs global market report 2018Pharmaceutical drugs global market report 2018
Pharmaceutical drugs global market report 2018
lakshmipraneethganti
 
A Crisis of Trust? Pharma and Healthcare Beyond 2016
A Crisis of Trust? Pharma and Healthcare Beyond 2016A Crisis of Trust? Pharma and Healthcare Beyond 2016
A Crisis of Trust? Pharma and Healthcare Beyond 2016
CARMA
 
Janssen full analysis.pptx
Janssen full analysis.pptxJanssen full analysis.pptx
Janssen full analysis.pptx
Marina Ibrahim
 
Ims global use_of_meds_report_2013
 Ims global use_of_meds_report_2013 Ims global use_of_meds_report_2013
Ims global use_of_meds_report_2013
Utai Sukviwatsirikul
 
Health & Wellness: Drug Stores Empower Self-care
Health & Wellness:  Drug Stores Empower Self-careHealth & Wellness:  Drug Stores Empower Self-care
Health & Wellness: Drug Stores Empower Self-care
TrustRobin
 
Roche Diagnostics
Roche DiagnosticsRoche Diagnostics
Roche Diagnostics
love4mihir
 
HPAPI DS/DP Manufacturing - Industry Trends
HPAPI DS/DP Manufacturing - Industry TrendsHPAPI DS/DP Manufacturing - Industry Trends
HPAPI DS/DP Manufacturing - Industry Trends
DrReddysCPS
 
Presentation20190103 final
Presentation20190103 finalPresentation20190103 final
Presentation20190103 final
Wayne Wei
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit Ghoshal
Anup Soans
 
A project report on financial analysis of novartis india (1)
A project report on financial analysis of novartis india (1)A project report on financial analysis of novartis india (1)
A project report on financial analysis of novartis india (1)
yashicaj9
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical Industry
Engr. Carlo Senica, MBA, CPSM
 
Medicines outlook through_2016_report (1)
Medicines outlook through_2016_report (1)Medicines outlook through_2016_report (1)
Medicines outlook through_2016_report (1)
Juan Manuel Santa Maria
 
Marrying Medical Affairs with Marketing
Marrying Medical Affairs with MarketingMarrying Medical Affairs with Marketing
Marrying Medical Affairs with Marketing
Anup Soans
 

Similar to Corporate reputation of pharma in 2016 (20)

Biosimilars discussion on Twitter
Biosimilars discussion on TwitterBiosimilars discussion on Twitter
Biosimilars discussion on Twitter
 
Marketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA ProgramMarketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA Program
 
Ethics in the Workplace Case Competition
Ethics in the Workplace Case CompetitionEthics in the Workplace Case Competition
Ethics in the Workplace Case Competition
 
Insights success the 10 fastest growing pharmaceutical companies oct 2017
Insights success the 10 fastest growing pharmaceutical companies oct 2017Insights success the 10 fastest growing pharmaceutical companies oct 2017
Insights success the 10 fastest growing pharmaceutical companies oct 2017
 
Kim_Dongok_VRX_ENDP
Kim_Dongok_VRX_ENDPKim_Dongok_VRX_ENDP
Kim_Dongok_VRX_ENDP
 
Final Campaign for IMC 618 at WVU
Final Campaign for IMC 618 at WVUFinal Campaign for IMC 618 at WVU
Final Campaign for IMC 618 at WVU
 
EVA pharma document
EVA pharma documentEVA pharma document
EVA pharma document
 
Pharmaceutical drugs global market report 2018
Pharmaceutical drugs global market report 2018Pharmaceutical drugs global market report 2018
Pharmaceutical drugs global market report 2018
 
A Crisis of Trust? Pharma and Healthcare Beyond 2016
A Crisis of Trust? Pharma and Healthcare Beyond 2016A Crisis of Trust? Pharma and Healthcare Beyond 2016
A Crisis of Trust? Pharma and Healthcare Beyond 2016
 
Janssen full analysis.pptx
Janssen full analysis.pptxJanssen full analysis.pptx
Janssen full analysis.pptx
 
Ims global use_of_meds_report_2013
 Ims global use_of_meds_report_2013 Ims global use_of_meds_report_2013
Ims global use_of_meds_report_2013
 
Health & Wellness: Drug Stores Empower Self-care
Health & Wellness:  Drug Stores Empower Self-careHealth & Wellness:  Drug Stores Empower Self-care
Health & Wellness: Drug Stores Empower Self-care
 
Roche Diagnostics
Roche DiagnosticsRoche Diagnostics
Roche Diagnostics
 
HPAPI DS/DP Manufacturing - Industry Trends
HPAPI DS/DP Manufacturing - Industry TrendsHPAPI DS/DP Manufacturing - Industry Trends
HPAPI DS/DP Manufacturing - Industry Trends
 
Presentation20190103 final
Presentation20190103 finalPresentation20190103 final
Presentation20190103 final
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit Ghoshal
 
A project report on financial analysis of novartis india (1)
A project report on financial analysis of novartis india (1)A project report on financial analysis of novartis india (1)
A project report on financial analysis of novartis india (1)
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical Industry
 
Medicines outlook through_2016_report (1)
Medicines outlook through_2016_report (1)Medicines outlook through_2016_report (1)
Medicines outlook through_2016_report (1)
 
Marrying Medical Affairs with Marketing
Marrying Medical Affairs with MarketingMarrying Medical Affairs with Marketing
Marrying Medical Affairs with Marketing
 

More from Market iT

LOI n o 2018-493 du 20 juin 2018 relative à la protection des données ...
LOI n o  2018-493  du 20 juin 2018   relative  à la protection  des données  ...LOI n o  2018-493  du 20 juin 2018   relative  à la protection  des données  ...
LOI n o 2018-493 du 20 juin 2018 relative à la protection des données ...
Market iT
 
Guide cnom-cnil : RGPD : le Conseil National de l’Ordre des Médecins et la CN...
Guide cnom-cnil : RGPD : le Conseil National de l’Ordre des Médecins et la CN...Guide cnom-cnil : RGPD : le Conseil National de l’Ordre des Médecins et la CN...
Guide cnom-cnil : RGPD : le Conseil National de l’Ordre des Médecins et la CN...
Market iT
 
Rapport du Sénat sur les MÉDICAMENTS INNOVANTS : CONSOLIDER LE MODÈLE FRANÇAI...
Rapport du Sénat sur les MÉDICAMENTS INNOVANTS : CONSOLIDER LE MODÈLE FRANÇAI...Rapport du Sénat sur les MÉDICAMENTS INNOVANTS : CONSOLIDER LE MODÈLE FRANÇAI...
Rapport du Sénat sur les MÉDICAMENTS INNOVANTS : CONSOLIDER LE MODÈLE FRANÇAI...
Market iT
 
Loi sapin II
Loi sapin IILoi sapin II
Loi sapin II
Market iT
 
Guide lanceur d'alerte
Guide lanceur d'alerteGuide lanceur d'alerte
Guide lanceur d'alerte
Market iT
 
TRansparency International : 2018 guide for whistleblowing legislation
TRansparency International : 2018 guide for whistleblowing legislationTRansparency International : 2018 guide for whistleblowing legislation
TRansparency International : 2018 guide for whistleblowing legislation
Market iT
 
SAPIN 2 : Decret lanceur d'alerte 19-04-2017
SAPIN 2 : Decret lanceur d'alerte 19-04-2017SAPIN 2 : Decret lanceur d'alerte 19-04-2017
SAPIN 2 : Decret lanceur d'alerte 19-04-2017
Market iT
 
Transparency International : Guide lanceur d'alerte
Transparency International : Guide lanceur d'alerteTransparency International : Guide lanceur d'alerte
Transparency International : Guide lanceur d'alerte
Market iT
 
Espace annonceurs PharmaCompliance.info tarifs_on_line
Espace annonceurs PharmaCompliance.info tarifs_on_lineEspace annonceurs PharmaCompliance.info tarifs_on_line
Espace annonceurs PharmaCompliance.info tarifs_on_line
Market iT
 
Guidelines on consent under GDPR
Guidelines on consent under GDPRGuidelines on consent under GDPR
Guidelines on consent under GDPR
Market iT
 
MedTech europe code of ethical business practice
MedTech europe code of ethical business practiceMedTech europe code of ethical business practice
MedTech europe code of ethical business practice
Market iT
 
Un logiciel peut il constituer un dispositif médical
Un logiciel peut il constituer un dispositif médicalUn logiciel peut il constituer un dispositif médical
Un logiciel peut il constituer un dispositif médical
Market iT
 
Le canard enchainé 2017.11.08 - des labos soignant l'éthique
Le canard enchainé   2017.11.08 - des labos soignant l'éthiqueLe canard enchainé   2017.11.08 - des labos soignant l'éthique
Le canard enchainé 2017.11.08 - des labos soignant l'éthique
Market iT
 
analyse d’impact relative à la protection des données (DPIA)
analyse d’impact relative à la protection des données (DPIA)analyse d’impact relative à la protection des données (DPIA)
analyse d’impact relative à la protection des données (DPIA)
Market iT
 
Mission « flash » sur le Levothyrox
Mission « flash » sur le Levothyrox Mission « flash » sur le Levothyrox
Mission « flash » sur le Levothyrox
Market iT
 
Programme universite des DPO - AFCDP 24 janvier 2018
Programme universite des DPO - AFCDP 24 janvier 2018Programme universite des DPO - AFCDP 24 janvier 2018
Programme universite des DPO - AFCDP 24 janvier 2018
Market iT
 
Cybersécurité des dispositifs médicaux
Cybersécurité des dispositifs médicauxCybersécurité des dispositifs médicaux
Cybersécurité des dispositifs médicaux
Market iT
 
HAS Rapport annuel deontologue_2016
HAS Rapport annuel deontologue_2016HAS Rapport annuel deontologue_2016
HAS Rapport annuel deontologue_2016
Market iT
 
Codeem rapport d'activité 2016
Codeem rapport d'activité 2016Codeem rapport d'activité 2016
Codeem rapport d'activité 2016
Market iT
 
Violation of the anti gift law ceo fined a record level 75000€
Violation of the anti gift law ceo fined a record level 75000€Violation of the anti gift law ceo fined a record level 75000€
Violation of the anti gift law ceo fined a record level 75000€
Market iT
 

More from Market iT (20)

LOI n o 2018-493 du 20 juin 2018 relative à la protection des données ...
LOI n o  2018-493  du 20 juin 2018   relative  à la protection  des données  ...LOI n o  2018-493  du 20 juin 2018   relative  à la protection  des données  ...
LOI n o 2018-493 du 20 juin 2018 relative à la protection des données ...
 
Guide cnom-cnil : RGPD : le Conseil National de l’Ordre des Médecins et la CN...
Guide cnom-cnil : RGPD : le Conseil National de l’Ordre des Médecins et la CN...Guide cnom-cnil : RGPD : le Conseil National de l’Ordre des Médecins et la CN...
Guide cnom-cnil : RGPD : le Conseil National de l’Ordre des Médecins et la CN...
 
Rapport du Sénat sur les MÉDICAMENTS INNOVANTS : CONSOLIDER LE MODÈLE FRANÇAI...
Rapport du Sénat sur les MÉDICAMENTS INNOVANTS : CONSOLIDER LE MODÈLE FRANÇAI...Rapport du Sénat sur les MÉDICAMENTS INNOVANTS : CONSOLIDER LE MODÈLE FRANÇAI...
Rapport du Sénat sur les MÉDICAMENTS INNOVANTS : CONSOLIDER LE MODÈLE FRANÇAI...
 
Loi sapin II
Loi sapin IILoi sapin II
Loi sapin II
 
Guide lanceur d'alerte
Guide lanceur d'alerteGuide lanceur d'alerte
Guide lanceur d'alerte
 
TRansparency International : 2018 guide for whistleblowing legislation
TRansparency International : 2018 guide for whistleblowing legislationTRansparency International : 2018 guide for whistleblowing legislation
TRansparency International : 2018 guide for whistleblowing legislation
 
SAPIN 2 : Decret lanceur d'alerte 19-04-2017
SAPIN 2 : Decret lanceur d'alerte 19-04-2017SAPIN 2 : Decret lanceur d'alerte 19-04-2017
SAPIN 2 : Decret lanceur d'alerte 19-04-2017
 
Transparency International : Guide lanceur d'alerte
Transparency International : Guide lanceur d'alerteTransparency International : Guide lanceur d'alerte
Transparency International : Guide lanceur d'alerte
 
Espace annonceurs PharmaCompliance.info tarifs_on_line
Espace annonceurs PharmaCompliance.info tarifs_on_lineEspace annonceurs PharmaCompliance.info tarifs_on_line
Espace annonceurs PharmaCompliance.info tarifs_on_line
 
Guidelines on consent under GDPR
Guidelines on consent under GDPRGuidelines on consent under GDPR
Guidelines on consent under GDPR
 
MedTech europe code of ethical business practice
MedTech europe code of ethical business practiceMedTech europe code of ethical business practice
MedTech europe code of ethical business practice
 
Un logiciel peut il constituer un dispositif médical
Un logiciel peut il constituer un dispositif médicalUn logiciel peut il constituer un dispositif médical
Un logiciel peut il constituer un dispositif médical
 
Le canard enchainé 2017.11.08 - des labos soignant l'éthique
Le canard enchainé   2017.11.08 - des labos soignant l'éthiqueLe canard enchainé   2017.11.08 - des labos soignant l'éthique
Le canard enchainé 2017.11.08 - des labos soignant l'éthique
 
analyse d’impact relative à la protection des données (DPIA)
analyse d’impact relative à la protection des données (DPIA)analyse d’impact relative à la protection des données (DPIA)
analyse d’impact relative à la protection des données (DPIA)
 
Mission « flash » sur le Levothyrox
Mission « flash » sur le Levothyrox Mission « flash » sur le Levothyrox
Mission « flash » sur le Levothyrox
 
Programme universite des DPO - AFCDP 24 janvier 2018
Programme universite des DPO - AFCDP 24 janvier 2018Programme universite des DPO - AFCDP 24 janvier 2018
Programme universite des DPO - AFCDP 24 janvier 2018
 
Cybersécurité des dispositifs médicaux
Cybersécurité des dispositifs médicauxCybersécurité des dispositifs médicaux
Cybersécurité des dispositifs médicaux
 
HAS Rapport annuel deontologue_2016
HAS Rapport annuel deontologue_2016HAS Rapport annuel deontologue_2016
HAS Rapport annuel deontologue_2016
 
Codeem rapport d'activité 2016
Codeem rapport d'activité 2016Codeem rapport d'activité 2016
Codeem rapport d'activité 2016
 
Violation of the anti gift law ceo fined a record level 75000€
Violation of the anti gift law ceo fined a record level 75000€Violation of the anti gift law ceo fined a record level 75000€
Violation of the anti gift law ceo fined a record level 75000€
 

Recently uploaded

Surat @Girls @ℂall 👄 XX000000XX 👄 With Cash Payment Home Delivery
Surat @Girls @ℂall 👄 XX000000XX 👄 With Cash Payment Home DeliverySurat @Girls @ℂall 👄 XX000000XX 👄 With Cash Payment Home Delivery
Surat @Girls @ℂall 👄 XX000000XX 👄 With Cash Payment Home Delivery
khandiya#G05
 
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptxHow to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
AmandaChou9
 
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Anindya Das Adhikary
 
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
MARIALUISADELROGONZL
 
Building a Strong Partnership with Your Medical Team
Building a Strong Partnership with Your Medical TeamBuilding a Strong Partnership with Your Medical Team
Building a Strong Partnership with Your Medical Team
bkling
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
Mithilesh Chaurasia
 
Introduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptxIntroduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptx
Dr. Dheeraj Kumar
 
EXTRACTION,_PHYTOCHEMICAL_SCREENING_&_FORMULATION_OF_BOERRHAVIA.pptx
EXTRACTION,_PHYTOCHEMICAL_SCREENING_&_FORMULATION_OF_BOERRHAVIA.pptxEXTRACTION,_PHYTOCHEMICAL_SCREENING_&_FORMULATION_OF_BOERRHAVIA.pptx
EXTRACTION,_PHYTOCHEMICAL_SCREENING_&_FORMULATION_OF_BOERRHAVIA.pptx
AbhashSingh12
 
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
PVI, PeerView Institute for Medical Education
 
Subcutaneous nodules in rheumatic diseases Ahmed Yehia Assistant Professor of...
Subcutaneous nodules in rheumatic diseases Ahmed Yehia Assistant Professor of...Subcutaneous nodules in rheumatic diseases Ahmed Yehia Assistant Professor of...
Subcutaneous nodules in rheumatic diseases Ahmed Yehia Assistant Professor of...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
Bright Chipili
 
Hypothyroidism / Underactive thyroid gland presentation
Hypothyroidism / Underactive thyroid gland presentationHypothyroidism / Underactive thyroid gland presentation
Hypothyroidism / Underactive thyroid gland presentation
riyaramesh2003
 
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsxDr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi
 
High Class Girls Call Delhi 9711199171 Provide Best And Top Girl Service And ...
High Class Girls Call Delhi 9711199171 Provide Best And Top Girl Service And ...High Class Girls Call Delhi 9711199171 Provide Best And Top Girl Service And ...
High Class Girls Call Delhi 9711199171 Provide Best And Top Girl Service And ...
sonamrawat5631
 
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
ailynolive
 
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
Sarthi Life Sciences
 
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdfHeart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
MedicoseAcademics
 
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
paridubey2024#G05
 
Lymphoma Made Easy , New Teaching Lectures
Lymphoma Made Easy , New Teaching LecturesLymphoma Made Easy , New Teaching Lectures
Lymphoma Made Easy , New Teaching Lectures
MiadAlsulami
 
Pernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptxPernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptx
Dr. vaishali Kadam
 

Recently uploaded (20)

Surat @Girls @ℂall 👄 XX000000XX 👄 With Cash Payment Home Delivery
Surat @Girls @ℂall 👄 XX000000XX 👄 With Cash Payment Home DeliverySurat @Girls @ℂall 👄 XX000000XX 👄 With Cash Payment Home Delivery
Surat @Girls @ℂall 👄 XX000000XX 👄 With Cash Payment Home Delivery
 
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptxHow to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
 
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
 
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
 
Building a Strong Partnership with Your Medical Team
Building a Strong Partnership with Your Medical TeamBuilding a Strong Partnership with Your Medical Team
Building a Strong Partnership with Your Medical Team
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
 
Introduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptxIntroduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptx
 
EXTRACTION,_PHYTOCHEMICAL_SCREENING_&_FORMULATION_OF_BOERRHAVIA.pptx
EXTRACTION,_PHYTOCHEMICAL_SCREENING_&_FORMULATION_OF_BOERRHAVIA.pptxEXTRACTION,_PHYTOCHEMICAL_SCREENING_&_FORMULATION_OF_BOERRHAVIA.pptx
EXTRACTION,_PHYTOCHEMICAL_SCREENING_&_FORMULATION_OF_BOERRHAVIA.pptx
 
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
 
Subcutaneous nodules in rheumatic diseases Ahmed Yehia Assistant Professor of...
Subcutaneous nodules in rheumatic diseases Ahmed Yehia Assistant Professor of...Subcutaneous nodules in rheumatic diseases Ahmed Yehia Assistant Professor of...
Subcutaneous nodules in rheumatic diseases Ahmed Yehia Assistant Professor of...
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
 
Hypothyroidism / Underactive thyroid gland presentation
Hypothyroidism / Underactive thyroid gland presentationHypothyroidism / Underactive thyroid gland presentation
Hypothyroidism / Underactive thyroid gland presentation
 
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsxDr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
 
High Class Girls Call Delhi 9711199171 Provide Best And Top Girl Service And ...
High Class Girls Call Delhi 9711199171 Provide Best And Top Girl Service And ...High Class Girls Call Delhi 9711199171 Provide Best And Top Girl Service And ...
High Class Girls Call Delhi 9711199171 Provide Best And Top Girl Service And ...
 
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
 
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
 
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdfHeart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
 
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
 
Lymphoma Made Easy , New Teaching Lectures
Lymphoma Made Easy , New Teaching LecturesLymphoma Made Easy , New Teaching Lectures
Lymphoma Made Easy , New Teaching Lectures
 
Pernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptxPernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptx
 

Corporate reputation of pharma in 2016

  • 1. PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST , 2017 page 1 of 7 ‘Corporate Reputation of Pharma in 2016— The Patient Perspective' EMBARGOED PRESS RELEASE 6AM, GMT, TUESDAY MARCH 21ST, 2017 ~ CONTACT: ALEX WYKE ~ TEL: +44 (0)1547-520-965 ~ EMAIL: REPORT@PATIENT-VIEW.COM ABOUT THIS REPORT AND SURVEY  Results drawn from survey conducted: November 2016 to early-February 2017.  Feedback from the patient groups surveyed: 1,463 patient groups; 46+ specialties; 105 countries.  Survey conducted in 16 languages: Japanese, Korean and Hungarian were new additions in 2016 (and had an impact on the survey results).  Industry analyses: compared with other healthcare sectors; assessed for a wide range of activities, and across different geographic areas.  Recommendations from respondent patient groups: how to improve corporate reputation.  Company analyses: 47 pharma companies, assessed on seven indicators of corporate reputation.  Pharma companies tell their own story on patient centricity: AbbVie; Eisai; Janssen (Pharmaceutical Companies of Johnson & Johnson); LEO Pharma; Lundbeck; Novartis; Servier; and ViiV Healthcare.  Report length: 227 pages. For the purposes of this report, the phrase 'corporate reputation' is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.
  • 2. PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST , 2017 page 2 of 7 The 47 companies analysed in this 2016 report AbbVie I Allergan I Almirall I Amgen I Astellas Pharma I AstraZeneca I Bayer I Bial (new for 2016) I Biogen I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Chiesi Farmaceutici I Eisai I Eli Lilly (Lilly) I Ferring I Gedeon Richter I Gilead Sciences I Grifols I Grünenthal I GSK I Hospira I Ipsen I Janssen (Pharmaceutical Companies of Johnson & Johnson) I LEO Pharma I Lundbeck I Mallinckrodt I Menarini I Merck & Co I Merck KGaA I Mylan I Novartis I Novo Nordisk I Octapharma I Otsuka I Pfizer I Roche I Sandoz I Sanofi I Servier I Shire I Stada Arzneimittel I Takeda I Teva I UCB I Valeant I ViiV Healthcare. ASSESSING THE PHARMA INDUSTRY AND ITS COMPANIES The pharma industry's performance at corporate reputation is assessed by three types of measures (2011-2016) 1. How pharma's corporate reputation compares with that of seven other healthcare-industry sectors. 2. How pharma's corporate reputation has changed over the past five years. 3. How good or bad the pharma industry is at various activities. The seven indicators of corporate reputation used to assess the 47 pharma companies are: 1. Patient centricity. 2. .Patient information. 3. Patient safety. 4. Useful products. 5. Transparency. 6. Integrity. 7. Effectiveness of patient-group relationships (NEW for the 2016 analysis). HOW DID INDUSTRY FARE? Patient groups judged that the pharma industry's corporate reputation fell in 2016 - after having reached a high in 2015 (as assessed over a 2011-2016 six-year period).  Just 37.9% of respondent patient groups thought that the pharma industry had an "Excellent" or "Good" corporate reputation in 2016. 44.7% of patient groups had said the same in 2015.  In 2016, only 23% of patient groups thought that pharma's corporate reputation had improved over the previous five years. 28% of patient groups had said the same in 2015.  In 2016 (as in 2015), pharma continued to be ranked 5th out of eight healthcare sectors (ahead only of generics, for-profit, and not-for-profit health insurers).  Patient groups thought that pharma's ability to conduct activities of importance to patient groups declined in 2016. Patient groups were more sceptical in 2016 even about pharma's ability to innovate (an important patient-group measure of confidence in the industry).  Regarding the quality of pharma's innovation across several geographic areas: patient groups in New Zealand would seem to have the least confidence in pharma's ability to innovate; those in Greece, the most.
  • 3. PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST , 2017 page 3 of 7 Patient groups’ perceptions of the pharma industry 2011-2016, at various activities, Percentage of total responses each year, that stated the pharma industry was 'Excellent' or 'Good' at each activity
  • 4. PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST , 2017 page 4 of 7 HOW CAN PHARMA IMPROVE? Patient-groups' perceptions of the pharma industry (2011-2016) at innovation For different countries/regions; Percentage of total responses each year, that stated the pharma industry was 'Excellent' or 'Good' at each activity [number in brackets is the number of respondent patient groups] 14-point plan proposed by the 460+ patient groups that commented on how pharma can improve its patient centricity Numbers next to green bars refer to the frequency of comments
  • 5. PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST , 2017 page 5 of 7 HOW COMPANIES PERFORMED Corporate brand awareness The number/percentage of patient groups claiming familiarity with individual pharma companies gives an idea of a company's brand awareness within the patient community. In 2016:  63% of the 1,463 respondent patient groups claimed familiarity with Pfizer - making the company the most well-known worldwide among patient groups.  Following up were Novartis (60%), Roche (54%), Bayer (51%), and Merck & Co (42%). These five companies rank both high and low for corporate reputation in 2016. Thus, the results show that little correlation exists (at least among the larger multinationals) between familiarity and corporate reputation, as perceived by patient groups. Respondent patient groups were also asked to state which companies they had worked with in the past five years. In 2016:  Novartis ranked top, with 395 patient groups stating that they had worked with the company within the past five years.  Following up were Pfizer (329), Roche (316), AbbVie (247), Janssen (242), and Bayer (206). Companies with the best corporate reputation among patient groups in 2016  Overall top-tier companies: The average performance of each company across the seven indicators of corporate reputation allowed them to be positioned into one of three tiers. Eleven companies made it into the top tier, with averages of 20%+. (SEE TABLE ON NEXT PAGE)  ViiV Healthcare has made the remarkable achievement of being ranked not only 1st overall in 2016, but also 1st for all seven indicators of corporate reputation.  AbbVie ranks overall 2nd in 2016, and is also 2nd for six of the seven indicators of corporate reputation (the exception was high-quality products, for which it ranked 3rd).  New to the overall top tier is Grifols, up from 25th in 2015 to overall 6th in 2016. Shire is up from 21st in 2015 to overall 10th in 2016. The radical jump for both companies was due to positive feedback for them from haemophilia patient groups, which responded in greater numbers in 2016.  Pfizer has slipped out of the top tier, dropping one place to overall 12th in 2016. Pfizer, though, ranks in the top tier for four of the seven indicators of corporate reputation. Other high flyers  The responses in 2016 from haemophilia patient groups also increased the rankings of Octapharma (up from 42nd in 2015 to overall 24th in 2016).
  • 6. PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST , 2017 page 6 of 7  Allergan's jump in the rankings, from 39th in 2015 to overall 26th in 2016, was primarily due to favourable feedback from patient groups in Scandinavia, and from those based in South Asia/South-East Asia, as well as from the 35 respondent neurological patient groups worldwide that were familiar with the company.  Amgen, which jumped from 26th in 2015 to overall 19th in 2016, gained positive feedback from the 107 respondent cancer patient groups familiar with the company.  Chiesi jumped from 36th in 2015 to overall 30th in 2016, primarily due to positive feedback from rare-disease patient groups.  GSK jumped from 17th in 2015 to overall 13th in 2016, due to positive feedback from 36 patient groups from South Asia/South-East Asia, and 39 respiratory/allergy patient groups worldwide. Companies with the best corporate reputation among patient groups in 2016 High flyers Company Rank 2016 Rank 2015 Difference Gedeon Richter 20th 43th 23 Grifols 6th 25th 19 Octapharma 24th 42nd 18 Allergan 26th 39th 13 Shire 10th 21st 11 Amgen 19th 26th 7 Chiesi 30th 36th 6 GSK 13th 17th 4
  • 7. PRESS RELEASE: PATIENTVIEW, EMBARGO DATE: TUESDAY, MARCH 21ST , 2017 page 7 of 7 PROFILE OF RESPONDENT PATIENT GROUPS Numbers of patient groups